Search Results: Treatment + Colorectal Cancer + Stage 4 (8 results)
PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)
https://www.facingourrisk.org/research-clinical-trials/study/183/parp-inhibitor-niraparib-in-patients-with-inherited-or-tumor-palb2-mutations-in-advanced-solid-tumors-pavo
Treatment
Any advanced or metastatic solid tumor except ovarian or prostate
PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.
Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced cancers
This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.
Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer
https://www.facingourrisk.org/research-clinical-trials/study/181/combined-pembrolizumab-quavonlimab-mk-1308a-versus-other-treatments-in-people-with-msi-high-or-dmmr-stage-iv-colorectal-cancer
Treatment
Stage 4 colorectal cancer
The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic (stage IV) Colorectal Cancer.
A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/178/a-study-of-the-investigational-targeted-therapy-art4215-to-treat-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage.
Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib
https://www.facingourrisk.org/research-clinical-trials/study/133/treating-metastatic-pancreatic-colorectal-gastroesophageal-or-biliary-cancer-with-chemotherapy-and-rucaparib
Treatment
Metastatic colorectal, pancreatic, gastroesophageal or biliary tract cancer
This study is focused on patients with pancreatic, colorectal, gastroesophageal, or biliary (bile duct) cancer that has spread to other places in the body (metastasized).
Chemotherapy drugs, such as liposomal irinotecan and fluorouracil damage cancer cells. Targeted therapies such as rucaparib, can keep cancer cells from being able to repair damage.
This study will look at how the targeted therapy rucaparib works with chemotherapy in treating patients with metastatic pancreatic, colorectal, gastroesophageal, or biliary cancer. The study will measure the best dose and look at sides effects with this combination of drugs.
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.
Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study
https://www.facingourrisk.org/research-clinical-trials/study/126/chemotherapy-bevacizumab-andor-atezolizumab-for-dmmr-msi-h-metastatic-colorectal-cancer-commit-study
Treatment
This study is for people with metastatic colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment using an immunotherapy agent alone. This study is focused on patients who are determined to be mismatch-repair deficient (dMMR) or have an MSI-H diagnosis, which are commonly seen in people with Lynch syndrome.
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
https://www.facingourrisk.org/research-clinical-trials/study/112/nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw
Treatment
People with metastatic colorectal cancer that is MSI-High
The purpose of this study is to compare the benefit of the combination of immunotherapy agents Nivolumab plus Ipilimumab in patients who have Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer versus using Nivolumab as a single therapy or chemotherapy.
Additional Results on Clinicaltrials.gov Treatment + Colorectal Cancer + Stage 4
139 results
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
NCT ID: NCT03223779 (https://ClinicalTrials.gov/show/NCT03223779)
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
NCT ID: NCT03844750 (https://ClinicalTrials.gov/show/NCT03844750)
Immunotherapy for Third Line Metastatic Colorectal Cancer
NCT ID: NCT04444622 (https://ClinicalTrials.gov/show/NCT04444622)
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
NCT ID: NCT03087071 (https://ClinicalTrials.gov/show/NCT03087071)
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
NCT ID: NCT04017650 (https://ClinicalTrials.gov/show/NCT04017650)
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
NCT ID: NCT04616183 (https://ClinicalTrials.gov/show/NCT04616183)
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
NCT ID: NCT04693377 (https://ClinicalTrials.gov/show/NCT04693377)
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
NCT ID: NCT04599140 (https://ClinicalTrials.gov/show/NCT04599140)
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT ID: NCT04899908 (https://ClinicalTrials.gov/show/NCT04899908)
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT ID: NCT04587128 (https://ClinicalTrials.gov/show/NCT04587128)
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT ID: NCT04761614 (https://ClinicalTrials.gov/show/NCT04761614)
ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
NCT ID: NCT05743036 (https://ClinicalTrials.gov/show/NCT05743036)
Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques
NCT ID: NCT03151564 (https://ClinicalTrials.gov/show/NCT03151564)
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
NCT ID: NCT04895722 (https://ClinicalTrials.gov/show/NCT04895722)
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT ID: NCT05217446 (https://ClinicalTrials.gov/show/NCT05217446)
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
NCT ID: NCT04853043 (https://ClinicalTrials.gov/show/NCT04853043)
Glutamine PET Imaging Colorectal Cancer
NCT ID: NCT03275974 (https://ClinicalTrials.gov/show/NCT03275974)
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
NCT ID: NCT05704985 (https://ClinicalTrials.gov/show/NCT05704985)
ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis
NCT ID: NCT01815359 (https://ClinicalTrials.gov/show/NCT01815359)
Living Donor Liver Transplantation for CRC Liver Metastases
NCT ID: NCT05175092 (https://ClinicalTrials.gov/show/NCT05175092)
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
NCT ID: NCT03659448 (https://ClinicalTrials.gov/show/NCT03659448)
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
NCT ID: NCT05243862 (https://ClinicalTrials.gov/show/NCT05243862)
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
NCT ID: NCT05308446 (https://ClinicalTrials.gov/show/NCT05308446)
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
NCT ID: NCT05162755 (https://ClinicalTrials.gov/show/NCT05162755)
A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
NCT ID: NCT05167409 (https://ClinicalTrials.gov/show/NCT05167409)
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT ID: NCT05379595 (https://ClinicalTrials.gov/show/NCT05379595)
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
NCT ID: NCT04701476 (https://ClinicalTrials.gov/show/NCT04701476)
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
NCT ID: NCT04117945 (https://ClinicalTrials.gov/show/NCT04117945)
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
NCT ID: NCT04907539 (https://ClinicalTrials.gov/show/NCT04907539)
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
NCT ID: NCT04991948 (https://ClinicalTrials.gov/show/NCT04991948)
Study of Magrolimab Given Together With FOLFIRI/BEV in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT05330429 (https://ClinicalTrials.gov/show/NCT05330429)
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
NCT ID: NCT04729322 (https://ClinicalTrials.gov/show/NCT04729322)
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
NCT ID: NCT05223673 (https://ClinicalTrials.gov/show/NCT05223673)
A Study to Investigate LYL845 in Adults With Solid Tumors
NCT ID: NCT05573035 (https://ClinicalTrials.gov/show/NCT05573035)
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT ID: NCT05631574 (https://ClinicalTrials.gov/show/NCT05631574)
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
NCT ID: NCT05322590 (https://ClinicalTrials.gov/show/NCT05322590)
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
NCT ID: NCT02997228 (https://ClinicalTrials.gov/show/NCT02997228)
DNX-2440 for Resectable Colorectal Liver Metastasis
NCT ID: NCT04714983 (https://ClinicalTrials.gov/show/NCT04714983)
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
NCT ID: NCT04668976 (https://ClinicalTrials.gov/show/NCT04668976)
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
NCT ID: NCT04495621 (https://ClinicalTrials.gov/show/NCT04495621)
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
NCT ID: NCT05200442 (https://ClinicalTrials.gov/show/NCT05200442)
Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
NCT ID: NCT02600949 (https://ClinicalTrials.gov/show/NCT02600949)
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
NCT ID: NCT05576896 (https://ClinicalTrials.gov/show/NCT05576896)
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
NCT ID: NCT03668431 (https://ClinicalTrials.gov/show/NCT03668431)
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
NCT ID: NCT03203525 (https://ClinicalTrials.gov/show/NCT03203525)
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT04008030 (https://ClinicalTrials.gov/show/NCT04008030)
Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?
NCT ID: NCT05021263 (https://ClinicalTrials.gov/show/NCT05021263)
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NCT ID: NCT05678257 (https://ClinicalTrials.gov/show/NCT05678257)
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID: NCT05576077 (https://ClinicalTrials.gov/show/NCT05576077)
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
NCT ID: NCT04294160 (https://ClinicalTrials.gov/show/NCT04294160)
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://ClinicalTrials.gov/show/NCT05489211)
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT ID: NCT05425940 (https://ClinicalTrials.gov/show/NCT05425940)
Infusion System for Hepatic Cancer
NCT ID: NCT04684862 (https://ClinicalTrials.gov/show/NCT04684862)
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
NCT ID: NCT04164069 (https://ClinicalTrials.gov/show/NCT04164069)
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
NCT ID: NCT03366155 (https://ClinicalTrials.gov/show/NCT03366155)
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT ID: NCT04793958 (https://ClinicalTrials.gov/show/NCT04793958)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://ClinicalTrials.gov/show/NCT01174121)
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
NCT ID: NCT05061017 (https://ClinicalTrials.gov/show/NCT05061017)
A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
NCT ID: NCT04111172 (https://ClinicalTrials.gov/show/NCT04111172)
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
NCT ID: NCT04963283 (https://ClinicalTrials.gov/show/NCT04963283)
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
NCT ID: NCT04426669 (https://ClinicalTrials.gov/show/NCT04426669)
M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
NCT ID: NCT05286814 (https://ClinicalTrials.gov/show/NCT05286814)
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT ID: NCT03935893 (https://ClinicalTrials.gov/show/NCT03935893)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://ClinicalTrials.gov/show/NCT04704661)
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
NCT ID: NCT03965234 (https://ClinicalTrials.gov/show/NCT03965234)
EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
NCT ID: NCT05350501 (https://ClinicalTrials.gov/show/NCT05350501)
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
NCT ID: NCT05400122 (https://ClinicalTrials.gov/show/NCT05400122)
TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
NCT ID: NCT04873895 (https://ClinicalTrials.gov/show/NCT04873895)
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT ID: NCT05239143 (https://ClinicalTrials.gov/show/NCT05239143)
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
NCT ID: NCT03642067 (https://ClinicalTrials.gov/show/NCT03642067)
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
NCT ID: NCT04169347 (https://ClinicalTrials.gov/show/NCT04169347)
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
NCT ID: NCT04294264 (https://ClinicalTrials.gov/show/NCT04294264)
Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study
NCT ID: NCT04449679 (https://ClinicalTrials.gov/show/NCT04449679)
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT ID: NCT04929223 (https://ClinicalTrials.gov/show/NCT04929223)
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
NCT ID: NCT05593328 (https://ClinicalTrials.gov/show/NCT05593328)
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
NCT ID: NCT05733000 (https://ClinicalTrials.gov/show/NCT05733000)
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT ID: NCT05311618 (https://ClinicalTrials.gov/show/NCT05311618)
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
NCT ID: NCT04952753 (https://ClinicalTrials.gov/show/NCT04952753)
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
NCT ID: NCT05363605 (https://ClinicalTrials.gov/show/NCT05363605)
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT ID: NCT05253651 (https://ClinicalTrials.gov/show/NCT05253651)
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
NCT ID: NCT01365169 (https://ClinicalTrials.gov/show/NCT01365169)
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
NCT ID: NCT04672434 (https://ClinicalTrials.gov/show/NCT04672434)
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
NCT ID: NCT05572684 (https://ClinicalTrials.gov/show/NCT05572684)
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT ID: NCT04607421 (https://ClinicalTrials.gov/show/NCT04607421)
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
NCT ID: NCT05328908 (https://ClinicalTrials.gov/show/NCT05328908)
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
NCT ID: NCT04094688 (https://ClinicalTrials.gov/show/NCT04094688)
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT04913337 (https://ClinicalTrials.gov/show/NCT04913337)
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
NCT ID: NCT04117087 (https://ClinicalTrials.gov/show/NCT04117087)
A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
NCT ID: NCT05141721 (https://ClinicalTrials.gov/show/NCT05141721)
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
NCT ID: NCT05039177 (https://ClinicalTrials.gov/show/NCT05039177)
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NCT ID: NCT05215574 (https://ClinicalTrials.gov/show/NCT05215574)
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
NCT ID: NCT04511039 (https://ClinicalTrials.gov/show/NCT04511039)
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://ClinicalTrials.gov/show/NCT04771520)
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT ID: NCT04449874 (https://ClinicalTrials.gov/show/NCT04449874)
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
NCT ID: NCT05716295 (https://ClinicalTrials.gov/show/NCT05716295)
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT ID: NCT03845166 (https://ClinicalTrials.gov/show/NCT03845166)
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
NCT ID: NCT04670679 (https://ClinicalTrials.gov/show/NCT04670679)
A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors
NCT ID: NCT04892017 (https://ClinicalTrials.gov/show/NCT04892017)
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT ID: NCT04140526 (https://ClinicalTrials.gov/show/NCT04140526)
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
NCT ID: NCT04432857 (https://ClinicalTrials.gov/show/NCT04432857)
GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
NCT ID: NCT04083599 (https://ClinicalTrials.gov/show/NCT04083599)
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NCT ID: NCT03428958 (https://ClinicalTrials.gov/show/NCT03428958)
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT04666688 (https://ClinicalTrials.gov/show/NCT04666688)
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
NCT ID: NCT04329494 (https://ClinicalTrials.gov/show/NCT04329494)
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
NCT ID: NCT04535401 (https://ClinicalTrials.gov/show/NCT04535401)
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
NCT ID: NCT03368963 (https://ClinicalTrials.gov/show/NCT03368963)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://ClinicalTrials.gov/show/NCT05277051)
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT ID: NCT03947385 (https://ClinicalTrials.gov/show/NCT03947385)
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer
NCT ID: NCT03597581 (https://ClinicalTrials.gov/show/NCT03597581)
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
NCT ID: NCT03929666 (https://ClinicalTrials.gov/show/NCT03929666)
Phase 2 Study of DKN-01 in Colorectal Cancer
NCT ID: NCT05480306 (https://ClinicalTrials.gov/show/NCT05480306)
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
NCT ID: NCT04660929 (https://ClinicalTrials.gov/show/NCT04660929)
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
NCT ID: NCT05176483 (https://ClinicalTrials.gov/show/NCT05176483)
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NCT ID: NCT04068896 (https://ClinicalTrials.gov/show/NCT04068896)
A Study of PY314 in Subjects With Advanced Solid Tumors
NCT ID: NCT04691375 (https://ClinicalTrials.gov/show/NCT04691375)
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
NCT ID: NCT04682431 (https://ClinicalTrials.gov/show/NCT04682431)
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT ID: NCT03485209 (https://ClinicalTrials.gov/show/NCT03485209)
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://ClinicalTrials.gov/show/NCT04319757)
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://ClinicalTrials.gov/show/NCT02632448)
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
NCT ID: NCT04458259 (https://ClinicalTrials.gov/show/NCT04458259)
A Study of ASP3082 in Adults With Previously Treated Solid Tumors
NCT ID: NCT05382559 (https://ClinicalTrials.gov/show/NCT05382559)
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
NCT ID: NCT02649790 (https://ClinicalTrials.gov/show/NCT02649790)
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer
NCT ID: NCT05185947 (https://ClinicalTrials.gov/show/NCT05185947)
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
NCT ID: NCT05256381 (https://ClinicalTrials.gov/show/NCT05256381)
Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS
NCT ID: NCT05379985 (https://ClinicalTrials.gov/show/NCT05379985)
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors.
NCT ID: NCT05355701 (https://ClinicalTrials.gov/show/NCT05355701)
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT ID: NCT04699188 (https://ClinicalTrials.gov/show/NCT04699188)
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT ID: NCT04485013 (https://ClinicalTrials.gov/show/NCT04485013)
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT ID: NCT03715933 (https://ClinicalTrials.gov/show/NCT03715933)
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT ID: NCT03785249 (https://ClinicalTrials.gov/show/NCT03785249)
A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours
NCT ID: NCT02521844 (https://ClinicalTrials.gov/show/NCT02521844)
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT ID: NCT04579380 (https://ClinicalTrials.gov/show/NCT04579380)
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT ID: NCT05395052 (https://ClinicalTrials.gov/show/NCT05395052)
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
NCT ID: NCT05091346 (https://ClinicalTrials.gov/show/NCT05091346)
Phase 1a/1b Study of IGM-8444 Alone and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers
NCT ID: NCT04553692 (https://ClinicalTrials.gov/show/NCT04553692)
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
NCT ID: NCT05069935 (https://ClinicalTrials.gov/show/NCT05069935)
A Beta-only IL-2 ImmunoTherapY (ABILITY) Study
NCT ID: NCT05086692 (https://ClinicalTrials.gov/show/NCT05086692)
S0820, Adenoma and Second Primary Prevention Trial
NCT ID: NCT01349881 (https://ClinicalTrials.gov/show/NCT01349881)
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT ID: NCT02817633 (https://ClinicalTrials.gov/show/NCT02817633)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.